Cancer Therapy Targeting Splicing Variants

This Research Topic focuses on the emerging role of splicing variants as therapeutic targets in cancer, highlighting their influence on critical cancer processes such as angiogenesis, drug resistance, and immune evasion. While advances have been made in developing therapies using small-molecule compounds, antisense oligonucleotides, and antibody-based treatments targeting splicing variants, there remain significant gaps in understanding their mechanisms and clinical efficacy. Despite the promising potential of targeting splicing variants, there remain significant gaps in understanding their full impact and therapeutic utility. Current studies have begun to explore treatments using small-molecule compounds, antisense oligonucleotides (ASOs), and various antibody-based therapies, yet comprehensive insights into their mechanisms and efficacy are still needed.

This Research Topic aims to delve into the multifaceted approaches of targeting splicing variants in cancer therapy. The primary objective is to explore and elucidate the therapeutic potential of splicing variant-targeted treatments, addressing key questions about their mechanisms, effectiveness, and potential for integration into existing cancer treatment paradigms. By investigating these aspects, the research seeks to advance our understanding and develop more effective cancer therapies.

To gather further insights in the realm of cancer therapy targeting splicing variants, we welcome articles addressing, but not limited to, the following themes:

Mechanisms of action of small-molecule compounds targeting splicing regulators
Development and application of antisense oligonucleotides (ASOs) in cancer therapy
Innovations in monoclonal antibodies and antibody-drug conjugates targeting splicing isoforms
The role of bispecific and trispecific antibodies in targeting cancer-specific splicing variants
Advances in chimeric antigen receptor (CAR) T and CAR natural killer (NK) cell therapies
Case studies and clinical trials evaluating the efficacy of splicing variant-targeted treatments
Challenges and future directions in the therapeutic targeting of splicing variants in cancer
Therapeutic resistance and potential combination strategies with existing targeted or immunotherapies
Emerging technologies such as long-read and spatial transcriptomics for identifying splicing variants

We welcome submissions of original research, reviews, mini-reviews, methods, perspectives, community case studies, conceptual analysis, data reports, policy briefs, brief research reports, general commentaries, and opinions.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Data Report
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Data Report
• Editorial
• FAIR² Data
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Technology and Code

Keywords: splicing variants, cancer treatment, molecular medicine, splicing regulators

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.